{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-004880","form_type":"8-K","ticker":"ENSC","cik":"0001716947","company_name":"Ensysce Biosciences, Inc.","filed_at":"2025-02-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.570570+00:00","generated_at":"2026-05-27T03:33:33.611178+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"confidence":"high","headline":"Ensysce secures up to $10M R&D funding from Galephar in equity-based development deal","bullets":["Galephar commits up to $10 million to support R&D, manufacturing, and testing of PF614 and PF614-MPAR.","Ensysce issues 1% of outstanding shares as restricted stock vesting in thirds based on project milestones.","Development costs compensated with 50% restricted stock and 50% freely tradeable shares at 1.2x actual cost.","15-year term with IP created related to Ensysce's products owned exclusively by Ensysce.","Share price fixed using trailing five-day closing price; no future variable pricing permitted."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-004880","json":"https://secwatch.observer/filing/0001493152-25-004880.json","markdown":"https://secwatch.observer/filing/0001493152-25-004880.md","text":"https://secwatch.observer/filing/0001493152-25-004880.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1716947/000149315225004880/0001493152-25-004880-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1716947/000149315225004880/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T03:33:33.611178+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}